Pei D P
China-Japan Friendship Hospital, Beijing.
Zhonghua Wai Ke Za Zhi. 1990 Oct;28(10):625-7, 638-9.
In this communication, serum Ca19-9 was determined in a series of patients with benign and malignant GI diseases. It was found that CA19-9 was positive in 86.7% of 30 pancreatic cancer patients with an average level of 427.53 u/ml, the value was statistically different from that found in non-malignant control group. Serum CA19-9 determination, in this series, helped to make definite diagnosis of pancreatic cancer in 6 cases, in which B-mode ultrasonography failed to diagnose, and in another 3 cases in which CT scanning was unable to 'see' the tumors. The combination of CA19-9, B-mode ultrasonography, and CT made definite diagnosis in 100% of all 30 pancreatic cancer patients. The authors discussed the significance of CA19-9 determination in the diagnosis and differential diagnosis of pancreatic cancer.
在本报告中，对一系列患有良性和恶性胃肠道疾病的患者测定了血清CA19-9。结果发现，30例胰腺癌患者中有86.7%的CA19-9呈阳性，平均水平为427.53 u/ml，该值与非恶性对照组的结果有统计学差异。在本系列研究中，血清CA19-9测定有助于对6例B超未能诊断的胰腺癌以及另外3例CT扫描未能“发现”肿瘤的患者做出明确诊断。CA19-9、B超和CT联合使用使所有30例胰腺癌患者均得到了明确诊断。作者讨论了CA19-9测定在胰腺癌诊断和鉴别诊断中的意义。
